A coalition of consumer groups and unions hopes to convince the Federal Trade Commission to alter the terms of AbbVie’s (ABBV) proposed $63 billion acquisition of Allergan (AGN) by arguing the deal — as currently conceived — would thwart competition and unfairly maintain higher drug prices for consumers.
Trending:
Consumer groups and unions try again to block the AbbVie and Allergan merger